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Avian,  murine,  feline,  and  human  retroviruses  frequently  cause  immuno- 
suppression  in their respective hosts (1,  2).  The mechanisms by which immune 
reactivity is impaired remain speculative. Virus infection often results in immune 
hyporeactivity, but in some instances inactivated virus causes suppression inde- 
pendently  of cellular  infection  (3,  4).  Thus,  it  appears  likely  that  some  viral 
proteins themselves can directly induce immunosuppression. 
The  Friend  murine  leukemia  virus  complex  (FV) l  causes  severe  immuno- 
suppression when inoculated into adult or newborn mice (1). FV complex, which 
is composed of a replication-competent helper virus (F-MuLV) and a repli~zation- 
defective spleen focus-forming virus (SFFV), causes a  rapidly developing eryth- 
roleukemia in susceptible strains of adult mice. Early suppression of B lymphocyte 
immune functions and altered leukocyte migration have been reported (5-7). In 
some  instances,  cell-mediated  immune  functions  are  also  diminished  (8,  9). 
Kumar and  Bennet (10) and  Kumar et al.  (11) developed a  murine  model for 
studying genetic resistance to FV-induced immunosuppression.  They found that 
a non-H-2-1inked,  autosomal gene, Fv-3, regulated susceptibility to in vitro and 
in vivo FV-induced immunosuppression,  and proposed that Fv-3 acted by regu- 
lating the numbers or functions of suppressor T  cells (I 2,  13). 
Several other mouse genes have been found to affect the course of FV-induced 
erythroleukemia (14-17 and Table I).  In particular,  two genes found within the 
MHC (H-2) influence spontaneous recovery from leukemia,  probably by influ- 
encing development  of virus-specific T  cell-mediated  immune  responses  (16- 
18).  The  H-2  b/b genotype is associated with a  high  incidence of recovery com- 
pared to the H-2  a/b and H-2  "/a genotypes (17). In addition, a non-H-2-associated 
gene,  Rfv-3,  acts  in  a  complementary  fashion  with  H-2,  and  is  required  for 
recovery from leukemia (19).  In the presence of a  low-recovery H-2 genotype, 
H-2  a/b or H-2  a/a, the resistant Rfv-3  r/s genotype is associated with recovery from 
viremia and production of virus-specific antibodies that neutralize virus and lyse 
virus-infected cells in the presence of complement (19-21).  Nevertheless, these 
mice die from progressive leukemia. Conversely, low-recovery BALB/c, A/WySn 
and  A.BY  mice, .which  have  the  Rfv-3  s/s  genotype  fail  to  produce  anti-FV 
I Abbreviations used in  this paper."  AIDS, acquired immunodeficiency syndrome; FV,  Friend 
murine leukemia virus complex; F-MuLV, Friend murine leukemia helper virus; HTLV-III, human 
T cell leukemia/lymphoma (lymphotrophic) virus type  111; LAV, lymphadenopathy-associated  virus; 
MCF, mink cell focus-inducing; PBBS, phosphate buffered balanced salts; RAMlgG, rabbit anti- 
mouse IgG; SFFU, spleen focus-forming unit; SFFV, spleen focus-forming  virus. 
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antibodies,  and remain viremic until  death (20,  21).  Because of the influence of 
the Rfv-3 gene on the ability of FV-infected mice to make anti-FV antibodies,  it 
seemed  possible  that  this  gene  might  act  by  influencing  susceptibility  to  FV- 
induced immunosuppression.  This study was initiated to test this hypothesis. Our 
results  indicate  that  the  Rfv-3  gene  did  not  influence  FV-induced  immuno- 
suppression;  however,  immunosuppression  in  FV-infected  mice  was  strongly 
influenced  by  H-2  genotype.  Mice  having  the  H-2  "/b  genotype  were  less  sup- 
pressed  than  mice  having  the  H-2  ~/a  genotype.  This  suppression  not  only  ap- 
peared to be independent  of the occurrence of FV-induced viremia and spleno- 
megaly, but also was independent of recovery from FV leukemia. 
Materials  and  Methods 
Animals.  C57BL/10SnJ, B10.A/SgSnJ, A.BY/SnJ, A/WySnJ, and BALB/cJ mice were 
purchased from The Jackson Laboratory, Bar Harbor, ME. F~ hybrids were bred at the 
Rocky Mountain  Laboratories,  Hamilton,  MT  (16).  Mice used  in all experiments  were 
between  2 and 6  mo of age.  Pertinent information concerning mouse genes relevant to 
recovery from Friend virus is summarized in Table I. 
Virus.  The  B-tropic  strain  of FV  complex  was obtained  from  Dr.  F.  Lilly,  Albert 
Einstein School of Medicine, Bronx, NY. Virus stocks used for inoculation were prepared 
in BALB/cJ mice and assayed as previously described (16). 
Animal Inoculations.  The virus stock was thawed and diluted  in phosphate buffered 
balanced salt  solution  (PBBS) containing 2%  FCS.  Mice were inoculated intravenously 
with 0.5 ml of diluted  virus stock, which contained ~1,000  spleen  focus-forming units 
(SFFU) and 4,000 fluorescent focus-forming units of F-MuLV (22). Mice were immunized 
by i.p.  inoculation of either 0.25  ml of a  10%  suspension of washed SRBC or  10 gg of 
TNP-Ficoll (Biosearch, San Rafael, CA). At appropriate intervals, spleens were removed, 
dissociated  into  single-cell  suspensions,  and  assayed  for either  anti-SRBC  or anti-TNP 
PFC. 
Assays.  The number of splenic anti-SRBC IgM- and IgG-secreting cells was determined 
by using the slide monolayer technique of Cunningham and Szenberg (23).  Both direct 
and anti-mouse  Ig-facilitated PFC responses were determined.  The peak primary IgM 
TABLE  I 
Comparison of H-2 and Rfv-3 Genotypes and Parameters of Recovery From Friend Disease in 
Various Mouse Strains 
Production  Recovery  Recovery from 
Mouse strain  H-2  Rfv-3  of anti-FV  from  leukemic 
genotype  genotype  antibody*  viremia*  splenomegaly* 
(C57BL/10 × A.BY)F~  b/b  r/s  +  +  + 
(BI0.A × A.BY)FI  a/b  r/s  +  +  -  or +§ 
(B10.A × A/WySn)FI  a/a  r/s  +  +  - 
A.BY  b/b  s/s  -  -  - 
A/WySn  a/a  s/s  -  -  - 
BALB/c  d/d  s/s  -  -  - 
* All mouse strains tested were viremic (-10  ~ XC-PFU/ml, ~104 SFFU/ml) early after FV infection, 
but those having the Rfv-3  r/~ genotype developed  serum anti-FV antibody and began to clear the 
viremia about 25 d after infection (19-21, 25, and our unpublished  data). 
* All  mice  in  this  table  developed  leukemic  splenomegaly  (spleen wt  1-4 g)  10-15  d  after  FV 
inoculation.  Certain  strains (see table) recovered spontaneously  between  25 and 40 d postinocula- 
tion, and spleen weights remained normal thereafter (16,  17). 
Using  a  viral dose  of 1,000  SFFU,  (B10.A  X A.BY)F1 mice did not recover from FV-induced 
splenomegaly. However, if given 100 or 10 SFFU, a significant number recovered (16, 17). MORRISON  ET  AL.  303 
and IgG PFC responses were previously determined to occur at 4 and 7 d postimmuni- 
zation, respectively. Therefore,  the antigen-specific IgM and  IgG PFC responses were 
determined by inoculating mice with SRBC 4 or 7 d before assay. To determine the PFC 
responses to a secondary immunization, mice were inoculated with SRBC and FV simul- 
taneously, boosted with SRBC 23 d  later, and assayed for antigen-specific IgM and IgG 
PFC 7 d after the booster immunization. Antigen-specific IgM PFC were defined as those 
plaques that developed without the addition of rabbit anti-mouse IgG (RAMIgG). The 
number of antigen-specific IgG-secreting PFC was determined by subtracting the direct 
PFC  response  from  the  facilitated  response.  The  number  of splenic  anti-TNP  IgM- 
secreting cells  was  determined  by using  the  slide  monolayer technique,  except TNP- 
conjugated SRBC were used (24).  Background anti-SRBC and anti-TNP PFC responses 
in unimmunized normal and FV-infected mice were consistently below 200 PFC/spleen. 
Plasma was collected at intervals after FV infection and SRBC immunization, and used 
to determine  circulating virus and  anti-SRBC antibody titers.  Titers  of F-MuLV were 
determined by plating plasma dilutions onto SC-1 cells and counting infected cell  foci 
visualized  by indirect immunofluorescence using F-MuLV-specific MAb 48, as described 
previously (22). 
Plasma samples  were divided and tested  for anti-SRBC antibodies either directly, or 
with the addition of RAMIgG, or after treatment with  2-ME.  Briefly,  50 #1 of serially 
diluted  plasma,  prepared  in  PBBS  containing 2%  FCS,  was added to the pelleted cells 
from 25 #1 of a  1% SRBC suspension. Anti-SRBC antibody titers were expressed as the 
reciprocal of the  highest  serum  dilution  that  showed a  distinct  agglutination pattern. 
Direct titers were determined by incubating plasma samples with SRBC for 4 h at 4°C. 
Indirect titers were determined by incubating plasma samples  with SRBC for 45 min at 
room temperature, washing three times with PBBS containing 2% FCS, adding 50 #1 of 
a  1:100 dilution of RAMIgG and incubating for 4 h at 4°C. Some plasma samples  were 
treated with 0.1  M 2-ME at 37°C for 30 min to inactivate IgM antibodies, diluted, added 
to SRBC, and incubated at 4°C for 4 h. 
Statistical Methods.  The Student's t test for unpaired data was used to determine the 
level of significance between the means of samples. 
Results 
Immunosuppression  in  Rfv-3 r/s and  Rfv-3 ~/~ Mice.  (B10.A  ×  A.WySn)F1, Rfv- 
3 'IS, mice were compared with BALB/c Rfv-3  ~/s mice for their ability to respond 
immunologically to SRBC. BALB/c mice were used as controls because of their 
known susceptibility to FV-induced immunosuppression (5), and their lack of a 
humoral immune response to FV during active infection (20 and Table I). The 
direct PFC response was assayed at 25 d after FV infection, and mice having the 
Rfv-3  r/s  genotype were  found  to  be  as  suppressed  as  mice  having the  Rfv-3  ~/s 
genotype (Table II). In both strains,  the direct PFC response was decreased by 
TABLE  II 
Effect of Rfv-3 Genotype on FV-induced Immunosuppression 
F-MuLV  Direct Anti-SRBC PFC/spleen  Rfv-3  viremia  Percent 
Strain  geno-  (PFU/  Uninfected  FV-infected suppression 
type  ml plasma) 
(B10.A × A/WySn)F~  r/s  1.2 × 103 ~  1.5  87,000  ~  1.10  300 ~  1.17  99.65 
BALB/c  s/s  7.5 × 104 ~  1.4  110,000  ~  1.07  480 ~ 1.26  99.56 
FV-infected mice were immunized with SRBC 21  d after infection. All mice were bled and then 
sacrificed for analysis of direct anti-SRBC PFC 4 d after SRBC immunization. Viremia was measured 
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>100-fold.  Thus,  the  Rfv-3  "/S genotype appeared  not  to  confer  resistance  to 
immunosuppression.  This  finding  was  surprising,  since  (B10.A  ×  A.WySn)F~ 
Rfv-3  '/S mice were capable of responding immunologically to FV, and most had 
reduced FV viremia by day 25 (Table I). 
Comparison of lmmunosuppression in H-2-congenic Mice Having the Rfv-3 r/s Gen- 
otype.  Genes within  the  H-2 complex have a  strong influence on  FV-induced 
leukemia.  By examining  congenic  Rfv-3  r/s  mice  that  differed  only at  the  H-2 
locus, we were able to study the effect of H-2 genotype on the development of 
FV-induced  immunosuppression.  We assayed the anti-SRBC immune  response 
of  FV-infected  mice  at  40  d  after  FV  inoculation,  when  these  mice  were 
responding immunologically to FV (Table I). At this time, H-2  a/a mice had gross 
splenomegaly  and  showed  depressed  7-d  IgG  anti-SRBC  PFC  responses  and 
lowered IgM anti-SRBC PFC levels at both times tested (4 and 7 d  post-SRBC 
immunization)  (Fig.  I).  At this  same time,  H-2  "/b mice also had  severe spleno- 
megaly,  but  showed  no  depression  in  anti-SRBC  PFC  of the  IgG  class,  and 
depression of the IgM PFC response only at 4 d postimmunization,  returning to 
normal  by day  7  (Fig.  1).  These  results  indicated  that  FV-induced  immuno- 
suppression  was  strongly  influenced  by  genes  within  the  H-2  complex.  As 
expected,  the  homozygous H-2  b/b genotype was associated with  both  recovery 
from  leukemia  and  lack  of immunosuppression  (data  not  shown).  However, 
heterozygous H-2  ~/b mice,  which  did not recover from  leukemia,  nevertheless 
failed to develop FV-induced  suppression of the IgG anti-SRBC response, and 
had only transient suppression of the IgM response. 
Kinetics ofFV-induced Immunosuppression.  To assess the role of viremia in FV- 
induced immunosuppression,  we studied the immune response of H-2  a/a Rfv-3  r/s 
mice at various times after FV infection.  Early (13 d) after FV-infection, when 
all  mice  were  viremic,  the  SRBC-specific IgG  PFC  response  was found  to  be 
depressed (Fig.  2). This response was also found to be suppressed (>l,000-fold) 
at 25 and 40 d post-FV inoculation, when most mice had eliminated the viremia. 
In contrast,  the 4- and  7-d antigen-specific IgM PFC responses were not signifi- 
cantly suppressed early after FV infection, but were suppressed later during the 
disease.  The  4-d  IgM  response  appeared  more  suppressed  than  the  7-d  IgM 
response at both 25 and 40 d after FV. 
In contrast to H-2  "/" mice, mice having the H-2  b/b or H-2  a/b genotypes did not 
have significantly suppressed  7 day IgM or IgG PFC responses early (13 d) or 
late (25 and  40 d) after  FV infection  (data not shown).  However, the 4-d IgM 
PFC  response  was found  to  be significantly  suppressed  (p <  0.001)  in  H-2  a/b 
mice, but not in  mice having  the  H-2  b/b genotype (data not shown).  Thus,  the 
influence  of H-2  genotype  on  FV-induced  immunosuppression  was  observed 
both early and late during disease. Furthermore, viremia alone was not sufficient 
for the  induction  of the  depressed  response,  since  mice  having  the  H-2  b/b or 
H-2  "/b genotype were viremic during  early disease (13 d), but were not immu- 
nosuppressed. 
Comparison of H-2-congenic Mice Having  the  Rfv-3 ~/~  Genotype.  We  studied 
H-2-congenic mice having the A strain background genes to assess the influence 
of H-2 genotype on FV-induced immunosuppression in Rfv-3  s/s mice. These mice 
do  not  produce  virus-neutralizing  antibody,  and  remain  viremic  until  death MORRISON  ET  AL.  305 
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FIGURE  1.  SRBC-specific IgM and lgG PFC responses of uninfected (0) and FV-infected (O) 
(B10.A  ×  A.BY)F],  H-2  a~', and (BI0.A  X  A/WySn)Fb H-2  a/a mice.  FV-infected mice were 
immunized with SRBC at either 33 d  (for 7-d PFC responses) or 36 d (for 4-d PFC response) 
after FV infection, and assayed for PFC responses at 40 d  post-FV inoculation. Both strains 
of mice had the Rfv-3  r/~ genotype and were nonviremic but had severe splenomegaly (>1 g) at 
this time. 
(Table I). A.BY (H-2  b/b) and A/WySn (H-2  "/a) mice were assayed for anti-SRBC 
PFC at 40 d  after FV infection, at which time both strains of mice had similar 
levels  of  viremia  (>105  FFU/ml).  The  IgM  PFC  responses  in  FV-infected 
A/WySn mice were slightly suppressed (less than one order of magnitude) at 4 
and  7  d  after SRBC immunization  (Fig.  3).  A.BY mice had  a  suppressed  IgM 
PFC response at  4  d  after SRBC-immunization  (<1.5  log10), but not at day 7. 
The IgG PFC response was suppressed in all H-2  a/a mice tested (p <  0.001), and 
the majority of these mice (five out of nine) were >99% suppressed. In contrast, 306  H-2  INFLUENCES  FRIEND  VIRUS-INDUCED  IMMUNOSUPPRESSION 
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FIGURE 2.  SRBC-specific IgM  and  lgG  PFC  responses of spleen cells from  FV-infected 
a/a  (B10.A X A/WySn)Fh H-2  mice were compared to responses of uninfected control mice at 
various times after FV infection. Mice were immunized with SRBC at either 4 or 7 d before 
assay.  Data were normalized to the control responses. (O) IgM PFC response 4 d after SRBC 
immunization. (O) IgM PFC response 7 d after SRBC immunization. (A) IgG PFC response 7 
d after SRBC immunization. Percentage of mice with viremia (>10 3 FFU/ml plasma) is also 
shown (m). 
in mice having the H-2  b/b genotype, immunosuppression of the IgG response was 
marginal (i.e., not significant at p <  0.001, but significant at p <  0.05), and only 
one animal was >99% suppressed. Thus, lack of severe suppression of the IgG 
PFC response correlated with the presence of the H-2 bm genotype, even in the 
presence of the Rfv-3  s/~ genotype and other A strain genes. 
Analysis of Plasma Anti-SRBC Antibody.  Plasma anti-SRBC antibody was mea- 
sured to determine whether the suppressed PFC responses were spleen-specific 
phenomena or whether the suppression was systemic. Plasma anti-SRBC antibody 
titers  were  reduced  in  FV-infected  H-2  a/a  mice  at  4  and  7  d  after  SRBC 
immunization (Table  III). The suppressed antibody responses correlated with 
the reduced PFC responses of these mice. Also, the lack of production of IgG 
anti-SRBC was evident, since most antibodies from FV-infected mice immunized 
7 d  previously.with SRBC were susceptible to inactivation by treatment with 2- 
ME, and thus were of the IgM class.  In contrast, antibodies obtained on day 7 
from control uninfected mice were not susceptible to this treatment. Plasma anti- 
SRBC antibody titers were performed in conjunction with all PFC assays.  In all 
instances, alterations in the PFC responses were reflected in the plasma antibody 
titers. Thus, the suppressed immunological responsiveness to SRBC appeared to 
be not only a local suppression of the PFC response in the spleen, but a systemic 
suppression of the humoral antibody response. 
Suppression  of Secondary Immune Response in H-2 a/a, Rfv-3 r/~ Mice.  To study 5.0 ¸ 
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FIGURE  3.  SRBC-specific IgM and lgG PFC responses of uninfected (0) and FV-infected (O) 
A.BY,  H-2  b/b, and A/WySn, H-2  a/= mice. FV-infected  mice were immunized with SRBC at 
either 33 d (for 7-d PFC responses) or 36 d (for 4-d PFC response) after FV infection, and 
assayed for PFC responses at 40 d post-FV inoculation. Both strains of mice had the Rfv-3  '/~ 
genotype and were viremic at this time. 
the  effect  of FV  infection  on  the  secondary  immune  response,  we  chose  to 
examine  H-2  a/", Rfv-3 "/S mice,  since  these  mice  responded  immunologically  to 
FV, but were suppressed to a primary  SRBC immunization.  These mice devel- 
oped a normal anti-SRBC  IgM  PFC response at 7  d after the secondary immu- 
nization, but had a depressed IgG response (Fig. 4). The majority of FV-infected 
mice  had  no  detectable  levels  of SRBC-specific  IgG  PFC,  and  those  that  did 
respond  had  significantly lower  levels  than  uninfected mice.  Also,  some  mice 
were  immunized with SRBC  7  d  before infection with  FV, boosted  23  d  after 
FV-infection, and assayed for PFC 7 d after the booster immunization  (data not 
shown). These mice developed normal IgM PFC responses, but had suppressed 308  H-2  INFLUENCES  FRIEND  VIRUS-INDUCED IMMUNOSUPPRESSION 
TABLE  III 






Anti-SRBC titer (logs)* 
Rabbit anti-mouse  Not treated  2-ME  Ig 
-  8.0 -  0  2.22 -  0.22  9.4-+ 0.16 
+*  3.5 __- 0.5 t  2.22 + 0.22  6.4 -  0.37 
-  10.0  -  0  10.0 -+ 0  13.8 + 0.13 
+  6.5 +- 0.46  3.25 --. 0.25  9.0 -+ 0.38 
* Mean -+ SE of the anti-SRBC titer of plasmas treated as described in Materials and Methods (8-10 
mice/group). 
* (B10.A × A/WySn)F~ mice were infected  with FV, immunized with SRBC 18 or 21  d later, and 
assayed 25 d after FV infection. 
Underscored values are significantly different from uninfected mice at p < 0.001. 
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FrGURr 4.  Secondary  PFC  responses  of  uninfected (Q)  and  FV-infected  (O)  (B10.A  x 
A/WySn)Fb H-2  a/a mice to SRBC. Two groups of seven mice per group were immunized with 
SRBC, and one group was inoculated with FV simultaneously. 23 d later, they were given a 
second SRBC immunization,  and SRBC-specific IgM and IgG PFC responses were determined 
/s  at 30 d after FV infection. These mice have the Rfv-3  r  genotype and were nonviremic  at this 
time. 
secondary IgG  PFC  responses.  Three  of four  FV-infected mice  had  IgG  PFC 
responses suppressed  by  90-99%.  Therefore,  the  secondary IgG response ap- 
peared to be sensitive to the effects of FV infection, even if the primary SRBC 
immunization was given before FV infection. 
Suppression of PFC Response to a  T  Cell-independent Antigen in H-2 ~/~, Rfv-3 ,/s 
Mice.  To  determine  whether  B  lymphocyte function was  altered  during  FV 
infection, we examined the PFC response of spleen cells from FV-infected mice 
to  the  T  cell-independent  antigen,  TNP-Ficoll.  (B10.A  X  A/WySn)F1, 
H-2  'l/~, Rfv-3  r/s mice failed to produce normal levels of direct TNP  PFC when 
assayed at 25 d  after FV infection (Table IV). This response was suppressed by 
>99%,  which  indicated that  B  lymphocyte function was  markedly reduced  in 
these FV-infected mice. MORRISON  ET  AL.  309 
TABLE  IV 
PFC Response to a  T Cell-independent Antigen in FV-infected 
H-2 a/a, Rfv-3 r# Mice 
Direct anti-TNP 
Infection  PFC/spleen*  Percent suppression 
None  53,456 ~  1.32  - 
FV  448 -g. 1.52  99.16' 
FV-infected (BI0.A x  A/WySn)F~ mice were immunized i.p. with 10 ug 
of TNP-Ficoll 21  d after infection. All mice were assayed for direct anti- 
TNP PFC 4 d after immunization with TNP-FicolI. 
* Numbers are the geometric mean ~SE factor of groups of five mice. 
* Significantly lower than uninfected mice (p <  0.001). 
Discussion 
Our results show that  genes within  the  H-2 complex influenced FV-induced 
immunosuppression. The IgG PFC response in mice having the H-2  ~/b or H-2  bm 
genotype was not  significantly  suppressed,  whereas  in  mice  having  the  H-2  a/a 
genotype, this response was suppressed both early (13 d) and late (25 and 40 d) 
during FV disease. In the case of (B 10.A X A/WySn)Fj, H-2 ~/~ mice, this finding 
was surprising, since these mice have the Rfv-3  r/s genotype and thus they respond 
immunologically to FV (19,  21). Our data indicated that  the  Rfv-3 gene alone 
did not appear to convey resistance to FV-induced immunosuppression. 
Only a  few studies have been concerned with defining the genetic regulation 
of FV-induced immunosuppression.  Kumar et al. (12, 13) described a gene, Fv-3, 
that  maps outside the  H-2 complex and  regulates susceptibility to FV-induced 
suppression of lymphocyte mitogenesis in vitro and to PFC responses in vivo. In 
our previous (18,  19, 21) and present experiments, we did not observe the effect 
of the Fv-3 gene.  This  may have been due to technical differences such as FV 
dose used, or to genetic differences in the mice tested. 
Massive splenomegaly often accompanies FV disease, and a depressed splenic 
PFC response could be due to alterations in specific splenic functions rather than 
general systemic immunosuppression.  However, several lines of evidence argue 
against this interpretation.  PFC responses were calculated as PFC/spleen and not 
PFC/10 ~ nucleated cells; therefore, the large number of nucleated leukemic ceils 
would  not  affect  the  calculation.  Also,  plasma  anti-SRBC  responses  were  de- 
pressed whenever we observed suppressed  PFC responses.  Thus,  we were ob- 
serving a  systemic suppression  and  not an  organ-specific phenomenon.  Lastly, 
mice having the H-2  "/b or H-2  ~/~ genotype had similarly enlarged spleens at both 
13 and 40 d after FV infection, but only H-2  "/a mice had a suppressed IgG PFC 
response. Therefore, FV-induced splenomegaly itself was not sufficient to cause 
this  immunosuppression.  However,  it  is  possible  that  FV-induced  changes  in 
splenic architecture could alter interactions among cells of the immune system. 
This  might  explain  the  transient  suppression  of the  IgM  PFC  responses  in 
splenomegalic H-2  "/b mice. 
Similarities  are  evident  between  the  immunosuppression  we  observed  in 
(B 10.A ×  A/WySn)F~ mice and that found previously in other susceptible strains 
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PFC responses were suppressed in FV-infected BALB/c mice (5, 26, 27). In some 
instances, serum antibody titers were also shown to be suppressed (5, 26). Our 
data indicated that the IgM PFC response was not as sensitive as the IgG PFC 
response  to  suppression,  since  the  IgM  PFC  response  was  only  transiently 
suppressed and returned to normal levels by 7-10 d after immunization (Figs.  1 
and  2),  whereas  both  the  primary  and  secondary  IgG  PFC  responses  were 
exquisitely sensitive to FV-induced immunosuppression (Figs.  1 and 4). 
The suppression we observed in both Ig classes could be due to altered B or 
T  cell  functions,  since  both  IgM  and  IgG  responses  to  SRBC  are  T  cell- 
dependent. However, since IgG responses require additional T cell help to make 
the class switch from IgM to IgG, the increased suppression of IgG PFC might 
be explained by lack of this T  cell function. By examining the immune response 
of FV-infected mice to a T  cell-independent antigen, B cell function could be 
tested directly.  (B10.A  X  A/WySn)F~,  H-2  a/a  mice failed to  generate normal 
numbers of PFC cells to TNP-FicoI1, which indicated that B lymphocyte function 
was  also  altered  (Table  IV).  Therefore,  FV-induced immunosuppression  ap- 
peared to  be  a  complex phenomenon probably  involving many different cell 
types of the immune system. This conclusion is consistent with previous obser- 
vations (28,  29)  that  FV  can infect and/or transform several different hemo- 
poietic cell types, including B and T  lymphocytes, myeloid cells, erythroid cells, 
and megakaryocytes. 
The mechanism(s) of retrovirus-induced immunosuppression is not well un- 
derstood. Both UV-inactivated retroviruses and retroviral components can be 
immunosuppressive, suggesting that  viral proteins may be responsible for the 
induction of the suppressed condition. In the feline leukemia virus system, UV- 
inactivated virus and pl 5E protein have been shown to cause suppression of the 
blastogenic response to T  cell mitogens, inhibition of inflammatory macrophage 
accumulation, and abrogation of tumor immunity (3, 4,  30-33).  However, our 
experiments indicated that high titers of F-MuLV helper virus were not solely 
responsible for the induction or maintenance of the suppressed condition. For 
instance, (B10.A  ×  A/WySn)F1 mice were viremic and suppressed early (13 d) 
during FV disease, and remained suppressed even after clearing the virus (40 d) 
(Figs.  1 and 2).  Also, only a  small percentage of spleen cells from these mice 
expressed viral proteins or released infectious virus (21,  34,  35).  Thus,  there 
must be a mechanism by which the immunosuppressed state was maintained even 
when levels of infectious virus and viral proteins were reduced by  1,000-fold. 
Conversely, A.BY mice had very high titers of circulating virus (>10 ~ FFU/ml), 
yet they were not severely immunosuppressed (Fig. 3).  Thus, in contrast to the 
feline system, it  appears  unlikely that circulating F-MuLV  helper virus or  F- 
MuLV  proteins  were the  sole  cause  of the induction  or  maintenance of the 
immunosuppression. 
The importance of the SFFV component of the FV complex in inducing the 
immunosuppressed condition is not known. SFFV has the genetic structure of a 
defective recombinant virus (36),  similar to dual-tropic recombinant mink cell 
focus (MCF)-inducing virus described previously (37,  38).  A  recent study by 
Mosier et al. (39) indicated that a  MuLV mixture containing MCF viruses was 
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Therefore, it is possible that SFFV might have a similar effect in the FV system. 
Furthermore,  our FV preparations contained nondefective MCF MuLV, which 
might have been involved in the immunosuppression observed. 
FV-infected (B10.A  ×  A/WySn)F1,  H-2  a/~ mice have interesting  analogies  to 
patients with acquired immunodeficiency syndrome (AIDS). (a) In both, a retro- 
virus infection leads to profound immunosuppression of adult immunocompetent 
hosts.  (b) Virus-specific antibodies are found in both cases (19, 21, 40-42),  yet 
both  are  immunologically  compromised  with  regard  to  new  immunological 
challenges (2). (c) Only low levels of infectious virus are found. In the FV system, 
this is due to the presence of antiviral antibodies (35), and in AIDS, the antiviral 
humoral response (40-42) might be partially responsible for the low number of 
infected  cells observed.  (d)  HTLV-III/LAV  causes a  marked  decrease  in  the 
number of T  helper cells, which results in an abnormal  helper/suppressor  cell 
ratio  (43,  44).  Although  we  have  no  data  concerning  this  ratio  in  (B10.A  × 
A/WySn)F1 mice, our data suggested altered T  helper cell function. The simi- 
larities of the two diseases and the common retroviral etiology warrant  further 
studies concerning  the virus-specific and  antigen-specific  immune  responses of 
this murine model. 
Recently,  the  Laterjet-Duplan  strain  of radiation  leukemia  virus was shown 
(39) to cause profound immunosuppression in mice having the H-2  b/b genotype. 
Conversely,  in  the  FV  system,  the  H-2  b/b genotype influences  recovery from 
disease and resistance to immunosuppression (17). Thus, in retrovirus infections, 
the same H-2 haplotype can have markedly different effects on recovery and/or 
immunosuppression, depending on the strain of retrovirus involved. By analogy, 
if there exist multiple retroviruses that cause AIDS (45, 46), it is possible that a 
single  HLA type might  have different effects on the susceptibility to different 
virus strains. 
Summary 
Friend murine leukemia virus complex (FV)-induced immunosuppression was 
studied by assaying splenic anti-SRBC PFC responses and plasma antibody titers 
in  mice  at  various  times  after  FV  inoculation.  Genes  located  within  the  H-2 
complex were found to influence resistance to FV-induced immunosuppression. 
Near  normal  responses  were  observed  in  mice  having  the  H-2  a/b  or  H-2  b/b 
genotype, whereas mice having the H-2  a/~ genotype were suppressed. This H-2 
effect  was  observed  not  only  in  mice  having  heterozygous  C57BL/10  ×  A 
background  genes,  including  Rfv-3  r/~,  but  also  was  apparent  in  mice  having 
homozygous A-strain background genes, including Rfv-3  ~/~. Therefore, the Rfv- 
3 gene did not appear to convey resistance to FV-induced immunosuppression. 
The suppression  in susceptible H-2  a/a mice was characterized  by a  partial  sup- 
pression of the IgM response and a  profound suppression of both the primary 
and secondary IgG responses. Neither splenomegaly nor viremia alone appeared 
to be sufficient for  the  induction  or  maintenance  of the  immunosuppression. 
The  mechanism  of suppression  was  unclear,  but  both  B  lymphocyte  and  T 
lymphocyte functions appeared to be altered. 
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